| Japanese |
|---|
| Title | 67Ga-citrateによる悪性腫瘍の診断 (第3報) - 動物実験について - |
|---|
| Subtitle | 原著 |
|---|
| Authors | 東与光*, 中山義之**, 秋場仁**, 伊藤勝雄*, 久田太郎***, 三木太平○, 川井邦男○○ |
|---|
| Authors(kana) | |
|---|
| Organization | *神奈川歯科大学 放射線学教室, **生化学教室, ***病理学教室, ○東京農業大学 分析化学教室, ○○東京薬科大学 (主任 馬場茂雄教授) |
|---|
| Journal | 核医学 |
|---|
| Volume | 8 |
|---|
| Number | 3 |
|---|
| Page | 155-164 |
|---|
| Year/Month | 1971/6 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「はじめに」1969年, Edwards, Hayesらが, 67Ga-citrateがホジキン病の頸部リンパ節病巣に選択的に取込まれ, シンチグラムで陽性像をえたと報告して以来, わが国でも, 67Ga-citrateによる悪性腫瘍の診断のこころみが多くの機関で行なわれ, その報告も多く注目されつつある. 私たちも, すでに第1, 2報を報告した. しかし. 67Ga-citrateの腫瘍への取込みの機転は依然として不明であり, その解明がいそがれている. かつ, 臨床経験を重ねるにつれ, 検討を要する多くの問題が伏在していることがわかり, 反省期ともいうべき時をむかえた. そこで, 私たちは, 動物実験により, その取込みの機序. Carrierや, 排泄の問題などを検討し, いささか所見をえたので, ここに第3報として報告したい. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | |
|---|
| English |
|---|
| Title | Diagnosis of Malignant Tumor With 67Ga-Citrate (3rd Report) |
|---|
| Subtitle | |
|---|
| Authors | Tomomitu HIGASI*, Yoshiyuki NAKAYAMA**, Chikashi AKIBA**, katsuo ITO*, Taro HISADA***, Tahe MIKI○, Kunio KAWAI○○ |
|---|
| Authors(kana) | |
|---|
| Organization | Kanagawa Dental College *Department of Radiology, **Department of Biochemistry, ***Department of Pathology, ○Tokyo Agricultural College, ○○Tokyo College of Pharmacy |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 8 |
|---|
| Number | 3 |
|---|
| Page | 155-164 |
|---|
| Year/Month | 1971/6 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Many investigators have been tried to find a good tumor-specific scanning aget for the diagnosis of malignant tumor, but as yet, success has been limited. In 1969, Edwards and Hayes unexpectedly noticed accumulations of 67Ga-citrate in the neck lymph nodes of patients with Hodgkin's disease while doing a bone scintiscan. We reported the results of our preliminary and secondary studies last year on 67Ga-citrate in connection with its accumulation within tumor tissues. Recently, the clinical aplications on diagnosis of malignant tumor with 67Ga-citrate are now under intensive investigation in other many hospitals. However, the mechanism of accumulation of 67Ga-citrate in the malignant tumor cells is as yet unknown. This paper is intended to report the results of our studies on the mechanlsm of accumulation of 67Ga-citrate in the animal tumor cell. The in vitro accumulation of 67Ga-citrate in Ehrlich's tumor cell rapidly increased as seen in figure 2. However, when 5 mM. EDTA was added to nutrient medium, which is presumed to inhibit the permeability of the cell membrane, accumulation of 67Ga-citrate in Ehrlich's tumor cell was scarcely detectable. On the other hand, when MMC (Mitomycin C) of anticancer agent was added to damage cell metabolism, accumulation of 67Ga-citrate in Ehrlich's tumor cell was greatly reduced as seen in the figure 3. The accumulation of 67Ga-citrate in tumor cell was impressed with the association with viability or function of the tumor cells. The strong affinity of 67Ga-citrate by the tumor cells, which is supported by the above-mentioned facts, is probably due to some difference in the tumor cell membrane which permits the permeation of 67Ga-citrate, although the involvement of 67Ga-citrate in intracellular metabolism has not yet been delineated. Electon microscopic examination of Ehrlich's tumor tissues showed scattered small granules with high electronic density in lysosome and they appeared to have something to do with 67Ga-citrate. That is, lysosome looked to be related with the uptake of 67Ga-citrate. This theory may also explain the uptake of 67Ga-citrate into inflammatory lesions. A study was made also on the distribution of synthesized chemical compounds such as Ga-lactate, pyruvate, tartarate, and gluconate in the organs of tumor bearing mice. The distribution of the above-mentioned 72Ga-compounds gave the same pattern as that of 72Ga-citrate as seen in the table 1. This result suggests that the initial active form of Gallium in the tumor localization process is anionic one. But the presence of the carriers changed the distribution of 67Ga-citrate (carrier-free) in the mice. When the carrier was present, the accutnlation of the 67G-citrate in bones and kidneys was greatly increased while the uptake in other organs such as tumor, liver and intestine was remarkably decreased as seen in the the whole-body autoradiogram of the figure 7. As a further experiment, the excretion following subcutaneous injection of 67Ga-citrate in Ehrlich's tumor-bearing mice was measured. Figure 5 shows the excretion curve of 67Ga-citrate. The excretion of 67Ga-citrate in feces was sigificantly and consistetly greater than that in urine, and the feces-to-urine ratio usually between about 4.5:1. When the carrier was present, the excretion of the 67Ga-citrate was greatly and rapidly increased, and the excretion of 67Ga-citrate in urine was significantly greater than that in feces. When Fesin (sacchrated ferric oxide) was injected on the previous day to Ehrlich's tumor bearing mice, the accumulation of 67Ga-citrate in liver was decreased while the nutake in tumor and bone was increased as seen in the table 5. The clinical application of Fesin was valuable for the visualization of the human malignant tumor. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | |
|---|